Actively Recruiting
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
Led by Gustave Roussy, Cancer Campus, Grand Paris · Updated on 2025-09-24
50
Participants Needed
7
Research Sites
150 weeks
Total Duration
On this page
Sponsors
G
Gustave Roussy, Cancer Campus, Grand Paris
Lead Sponsor
I
Ipsen
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of the study is to describe real-life use and exposition to nivolumab-cabozantinib among older patients with metastatic clear-cell renal cell cancer
CONDITIONS
Official Title
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 70 years old or older
- Confirmed advanced or metastatic renal-cell carcinoma
- No previous treatment in metastatic setting
- Performance Status 0 to 2
- Sexually active male patients agree to use condom during the study and for 5 months after last treatment; female partners should use effective contraception
- Able to understand, sign, and date informed consent
- Willing and able to comply with study visits and procedures
- Affiliated with a social security system or beneficiary of the same
You will not qualify if you...
- Participation in another clinical study with an investigational product within last 4 weeks and during study treatment (except certain CARE1 study participants)
- Performance Status greater than 2
- Contraindications to Cabozantinib and/or Nivolumab such as symptomatic untreated brain metastasis or active autoimmune disease requiring systemic immunosuppressants (thyroid or adrenal disorders not excluded)
- Severe cardiovascular or thrombo-embolic event in last 3 months
- Exclusive palliative care recommended
- Under guardianship, deprived of liberty, or incapable of giving consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Institut de Cancérologie de l'Ouest - Angers
Angers, France, 49055
Not Yet Recruiting
2
Centre Georges François Leclerc
Dijon, France, 21079
Not Yet Recruiting
3
Centre Léon Bérard
Lyon, France, 69373
Not Yet Recruiting
4
Hôpital Tenon
Paris, France, 75020
Not Yet Recruiting
5
Institut Universitaire Du Cancer Toulouse- Oncopole Claudius Regaud
Toulouse, France, 31059
Not Yet Recruiting
6
CHU Tours - Hôpital Bretonneau
Tours, France, 37044
Not Yet Recruiting
7
Gustave Roussy
Villejuif, France, 94800
Actively Recruiting
Research Team
M
Maxime Frelaut, MD
CONTACT
M
Maia Claveau CLAVEAU
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here